Table 2.

Summary of the adverse events that occurred in the two treatment groups (safety population)

Adverse event	Pertuzumab group [cases (%)] n = 83	Control group [cases (%)]n = 80
All-grade AEs	83 (100.0)	78 (97.5)
Grade 3–5 AEs	67 (80.7)	52 (65.0)
Serious AEs	17 (20.5)	12 (15.0)
AEs leading to treatment discontinuation	7 (8.4)	5 (6.3)
AEs with fatal outcome	3 (3.6)	6 (7.5)
AEs leading to study withdrawal	1 (1.2)	2 (2.5)

AE adverse event